According to TipRanks.com, Trucchio has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.1% and a 32.9% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $14.25 average price target, implying an 87.0% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock.
The company has a one-year high of $14.30 and a one-year low of $5.64. Currently, Gossamer Bio has an average volume of 1.08M.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GOSS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Read More on GOSS:
- Needham Thinks ViaSat’s Stock is Going to Recover
- H.C. Wainwright Thinks Gold Resource’s Stock is Going to Recover
- Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Mediwound (MDWD)
- Quest Diagnostics Buckles up to Fight Monkeypox
- Adtran (ADTN) Has a New Rating from Needham